figshare
Browse
ierh_a_1945919_sm5598.pdf (74.61 kB)

A consensus integrated care pathway for patients with primary biliary cholangitis: a guideline-based approach to clinical care of patients

Download (74.61 kB)
journal contribution
posted on 2021-07-08, 06:40 authored by Gideon M Hirschfield, Olivier Chazouillères, Helena Cortez-Pinto, Guilherme Macedo, Victor de Lédinghen, Femi Adekunle, Marco Carbone

Primary biliary cholangitis (PBC) is an infrequent, immune-mediated cholestatic liver disease, which can lead to liver fibrosis, cirrhosis and complications of end-stage liver disease. The established goals of treatment of PBC are prevention of end-stage liver disease and amelioration of associated symptoms. The European Association for the Study of the Liver (EASL) management guidelines provide extensive recommendations on the diagnosis and management of PBC.

This article describes the development by expert consensus of a ‘PBC Integrated Patient Care Pathway’ to simplify and standardize the management of PBC for clinicians based on current practice.

Guideline adoption is potentially poor in practice since most patients with PBC in the community are seen by general gastroenterologists or hepatologists without a special interest in autoimmune liver disease. The PBC Integrated Patient Care Pathway is a best practice tool for clinicians designed to complement the EASL Clinical Practice Guidelines for the diagnosis and management of PBC patients. It gives clinicians a practical decision tree of the key steps in PBC management, thereby providing a simplified framework and an opportunity for more uniform practice that supports the safe and timely adoption of varied models of care provision to patients with PBC.

Funding

The development meeting and production of the Patient Care Pathway have been organized and funded by Intercept Pharma Europe Ltd. There was no financial reward associated with writing the paper. Content Ed Net France provided editorial and medical writing assistance for the preparation of this manuscript; this assistance was funded by Intercept Pharma Europe Ltd. The views and opinions expressed are those of the authors and not necessarily those of Intercept Pharmaceuticals. The sponsor did not have any role in article preparation – study design/data analysis/statistical input/review of drafts/writing of the article/identification of papers for inclusion/any other form of input.

History